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TRENDS IN BEERS DRUG USE IN THE DUALLY ELIGIBLE MEDICARE
AND MEDICAID POPULATION USING THE 1997 BEERS DRUG LIST
FROM 1999 THROUGH 2004
Montgomery MA, Ciborowski G, Blackwell SA, Baugh DK
Centers for Medicare & Medicaid Services, Baltimore, MD, USA
OBJECTIVES: To examine rates of potentially inappropriate prescribing in a popula-
tion dually eligible for Medicare and Medicaid during the period 1999 through 2004. 
METHODS: Descriptive analyses (population parameter assessments) were conducted 
on the 1999 through 2004 Medicaid ﬁ les for elderly dually eligible enrollees. Inap-
propriate drugs independent of diagnosis as identiﬁ ed by the 1997, beers drug list
were analyzed. RESULTS: Proportionally, decreases in Beers drug use occurred in the 
initial year, 1999–2000; thereafter Beers drug use increased. The younger elderly (i.e., 
65–74 years old) showed an increase in Beers drug use from 1999 to 2004 (20%) 
while older elderly (age 85) showed a decrease in use (11%). Hispanics had the 
greatest increase in use of Beers drugs (13%) during the study period followed by
African-Americans (10%). Our results indicate that for central nervous system prod-
ucts prescribing patterns increased by 43.22% for the elderly dually-eligible popula-
tion during this period of time, followed by neuromuscular prescriptions (31.92 
percent) as compared to all Beers prescriptions dispensed. Within therapeutic category, 
we found that Beers drug use for neuromuscular drug products had the highest 
increase during the study period at 13.42% followed by central nervous system drugs 
at 4.57%. CONCLUSIONS: Our results underscore the need for medical professionals
to make a conscious effort to familiarize themselves with Beers drugs so that when 
treating the elderly these risks can be reduced. We found that Beers drug use among 
the younger elderly is rising. We also found that Beers drug use is increasing among 
the Hispanic-American and African-American populations.
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A SYSTEMATIC LITERATURE REVIEW OF ELECTRONIC MONITORING
DEVICES FOR MEASURING MEDICATION ADHERENCE
Shi L1, Koleva YN1, Chhabra P1, Walker PD1, Kalsekar A2, Pawaskar MD3
1Tulane University, New Orleans, LA, USA, 2Eli Lilly and Company, Indianapolis, IN, USA, 3Eli
Lilly and Company, Indianpolis, IN, USA
OBJECTIVES: Self-reported questionnaires provide an easy way to measure adher-
ence, however they can be subject to misrepresentation. This study reviewed electronic
monitoring devices for measuring adherence to oral, inhaled, and injectable medica-
tions. METHODS: The literature search was performed from 1980–2008 using
PubMed, PubMed In Process and Non-Indexed, OVID MEDLINE, PsycINFO 
(EBSCO), CINAHL (EBSCO), OVID HealthStar, EMBASE (Elsevier), and Cochrane
Databases. The following search terms were used: patient compliance, medication 
adherence, treatment compliance, drug monitoring, drug therapy, electronic, digital, 
computer, monitor, monitoring, drug, drugs, pharmaceutical preparations, compli-
ance, and medications. Two authors independently reviewed titles and abstracts, which
were ranked by 3-point scoring (1 point for monitoring device, 1 point for adherence
topic, and 1 point for medication) for relevance and publications were retrieved in 
full text for data extraction. Additionally, a search on the United States patents was 
performed for relevant information. RESULTS: From 1679 relevant citations, full-text 
review was conducted for 156 articles (scored 3 points), of which 123 studies (79%) 
used medication event management system (MEMS) caps. A total of 46 (30%) of all 
studies used electronic monitoring devices in clinical trial settings. Adherence was
monitored in 105 (67%) studies, most frequently in HIV/AIDS (n  26), followed by
hypertension (n  8), depression (n  7), diabetes (n  7), and asthma (n  6). Addi-
tionally, self-reported adherence was measured in 74 (47%) of studies and was found
to correlate moderately well with electronic measures of adherence. No peer-reviewed
studies using a monitoring device for injectable medications were found. Secondary
search found 21 US patents relevant to medication monitoring; particularly three were 
designed for injectable regimens. CONCLUSIONS: MEMS remains a dominant device
for measuring medication adherence. Commercialization of a device for measuring
adherence with injectable and inhaled regimens may address the gap in health out-
comes research for patients who have medical needs for these drugs.
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VARIABILITY OF FEES IN THE FIELD OF ULTRASOUND IN THE
AUSTRIAN CONTRACTED PHYSICIANS’ AND INSTITUTES’ SECTOR
Weisser A, Wilbacher I, Scholler C, Endel G
Main Association of Austrian Social Security Institutions, Vienna, Vienna, Austria
OBJECTIVES: Contracts with contracted physicians or institutes that perform health 
care services can provide price advantages due to competition. The sickness funds of 
the Austrian Social Security signed a contract concerning ultrasound with physicians 
or institutes. Claims data, respectively rendered fees suggest a possible savings poten-
tial in the fee for service system without reducing the scope of the procedures or the
frequencies. We analyzed the variety of fees in the ﬁ eld of ultrasound including con-
tracted physicians and institutes. This shows a variability among the total amount of 
reimbursement in the Austrian outpatient sector consisting of contracted physicians,
institutes and outpatient clinics of hospitals and ambulatories. Approximately 30% 
of the Austrian outpatient sector cannot be displayed since no data is available.
METHODS: Price differences for the same or similar procedures performed by differ-
ent contracted physicians or institutes are evaluated and displayed. Different ﬁ nancial 
impacts (e.g. focusing on average or lowest value) are simulated. Values were rounded
to two decimal points, however, calculated by 15 decimal points. The fee equals the
division of turnover/frequencies. RESULTS: A total of 78,131,670 ultrasound proce-
dures were brought into account in the year 2006. Calculating all frequencies with
the lowest paid fee (turnover/frequency) for each service would lead to a lower ﬁ nan-
cial effort of 40% compared to the current turnover. Calculating all frequencies with 
the highest fee for service would lead to a higher effort of 47% compared to the 
current turnover. CONCLUSIONS: A current savings potential of 47%, contrasting 
the current fee with the most expensive one, indicates a well established fee negotia-
tion. However, a savings potential of 40% is worth being considered for further evalu-
ation and, if necessary, the adjustment of fees is advisable.
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EQUITY AND ACCESS TO GENERIC DRUGS: A COMPARISON OF
GENERIC DRUG DISCOUNT PROGRAMS OFFERED BY CHAIN
PHARMACIES IN THE UNITED STATES
Dwibedi N1, Patel H1, Sansgiry SS2
1University of Houston, HOUSTON, TX, USA, 2University of Houston, Houston, TX, USA
OBJECTIVES: Wal-Mart Stores (WMS) was the ﬁ rst pharmacy to offer the Generic
Drug Discount Program (GDDP) in 2006. The objective of this study was to compare 
GDDPs offered by large chain pharmacies in the United States. METHODS: A pro-
spective cross-sectional ﬁ eld study was conducted by obtaining data (March 2008 to
November 2008) on GDDPs offered using a combination of telephone and face to
face interview technique. Data obtained from the pharmacy included GDDPs offered, 
type of GDDP (patient cost for 30/90 day supply {DS}), number and type of drugs 
covered. Data coded in an excel sheet was analyzed by considering the WMS program 
as a reference to evaluate similarities/differences among GDDPs. Comparison were 
further performed by matching drugs covered in each GDDP with the top 100 generics
(by units) consumed in the US in 2007. RESULTS: A total of 22 (of 37) pharmacies
offered GDDPs. The patient sharing cost ranged from $3.99 to $9.99 for a 30DS and 
from $9.99 to $15.99 for a 90DS. Seven GDDPs (31.8%) were similar to WMS 
program with respect to number of generics covered (300–400), cost for 30DS ($4),
and cost for 90 DS ($10). Four GDDPs (18.2%) were identiﬁ ed as not at par with 
the WMS program, while 10 (45.4%) were identiﬁ ed as superior. The superior GDDPs
offered more drugs (400), while the inferior programs offered the same or less 
number of drugs at a higher cost ($9.99 for 30DS, and $12.99-$15.99 for 90DS). The 
GDDPs varied by the number of top 100 drugs covered with 72.7% covering more 
or same number of top 100 drugs as WMS. CONCLUSIONS: GDDPs were different 
across pharmacies in terms of number and type of generic medications covered, and 
cost for 30/90 day supply. Patients can save on generic drugs if they make the right 
choices.
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UNMET PRESCRIPTION MEDICATION NEED DUE TO COST, HEALTH
PLAN PROBLEM, AND LACK OF INSURANCE OF CHILDREN IN THE
UNITED STATES: RESULTS FROM NATIONAL SURVEY OF CHILDREN’S
HEALTH 2003 DATA
Mehta S, Nagar SP, Aparasu R
University of Houston, Houston, TX, USA
OBJECTIVES: To examine the nature of unmet prescription medication need (UPMN) 
due to cost, health plan problem and lack of insurance using 2003 National Survey
of Children’s Health (NSCH). METHODS: A nationally representative sample of 
102,353 children under 18 years of age from 2003 and 2004 NSCH was used for 
analysis. Children who did not get all the prescription medication needed in the past
twelve months due to cost, health plan problem or lack of insurance were examined. 
Multivariate logistics models within the conceptual framework of Andersen’s Behav-
ioral Model were used to examine the predictors of UPMN due to cost, health plan
problem and lack of insurance. RESULTS: According to NSCH, 35.39% children did
not receive medications due to cost, 26.51 % due to health plan problem, and 40.73%
due to lack of insurance. Multivariate logistic regression for UPMN due to cost
revealed that children with attention deﬁ cit hyperactive disorder (Odds Ratio (OR), 
2.39) or asthma (OR, 3.15) were more likely to report UPMN due to cost and children 
having public insurance (OR, 0.26) or gained insurance (OR, 0.26) were less likely to 
report UPMN due to cost. Logistic regression model for UPMN due to health plan 
problem revealed that racial group other than whites and blacks (OR, 4.35), children 
with public insurance (OR, 11.98) and gained insurance (OR, 2.85) were more likely 
to report UPMN due to health plan problem. Lastly, children of 5–11 years (OR, 
11.18) and 12–17 years (OR, 6.15) were more likely to report UPMN due to lack of 
insurance. CONCLUSIONS: Several predisposing, enabling and need factors are asso-
ciated with UPMN due to cost, health plan problem and lack of insurance. Findings 
suggest that there is a need to focus on certain sociodemographic groups to improve 
access to prescription medication for children.
